Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series LLC LTD Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series LLC LTD : World’s leading Event Organizer

Back

12th World Cancer Conference

London, UK

Katharina Pachmann

Katharina Pachmann

SIMFO GmbH, Germany

Title: Maintrac® CTC detection as a tool to uncover the strategies of tumor cells to evade elimination

Biography

Biography: Katharina Pachmann

Abstract

The most fearful feature of malignant tumors is their ability to form distant metastases in vital organs leading to fatal outcome, therefore the most important task of tumor therapy is the prevention of metastasis formation. Metastases develop from cells that leave the tumor and travel via the blood until they find a niche to settle and grow. Different measures have been applied to detect tumors by screening before they might seed cells, destroy the disseminated cells by neoadjuvant and adjuvant chemotherapy and/or prevent them from regrowing by surveillance after primary therapy. However, all these actions are taken without being able to directly control to what extent they influence tumor cell dissemination. The maintrac® approach enables physicians and patients to timely and individually determine the effect of different therapeutic actions on dissemination and elimination from blood and to monitor the behavior of the circulating tumor cells during the whole course of disease by enumerating these cells at any time of point of the disease. Assumptions which have not been explainable before now can be confirmed by direct observation of the behavior of the circulating tumor cells. Surgery can lead to convey metastasis formation because it leads to tumor cell dissemination and activation. Chemotherapy is effective only in a fraction of patients because in some patients the circulating tumor cells become resistant against the drugs and can regrow in their presence. Hormone blocking silences the circulating tumor cells but in most cases is not able to eliminate them so they can regrow after stopping treatment. And finally, we are able to show that the circulating tumor cells can upregulate ligands which prevent immune cells from recognizing them. Thus, this method will in the future contribute to take action at the time when treatment shows insufficient effect and thus optimally tailor tumor therapy.